Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NYT article: Market flooded with fake Botox
https://www.nytimes.com/2024/04/25/well/live/counterfeit-botox-risks.html?unlocked_article_code=1.nU0.5syV.RaMIYrMIOJG_&smid=url-share
NYT article: Market flooded with fake Botox
https://www.nytimes.com/2024/04/25/well/live/counterfeit-botox-risks.html?unlocked_article_code=1.nU0.5syV.RaMIYrMIOJG_&smid=url-share
Mahesh Krishnan Elected to Halozyme's Board of Directors
April 25 2024 - 4:45PM
PR Newswire (US)
Alert
Print
Share On Facebook
SAN DIEGO, April 25, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the election of Mahesh Krishnan, M.D. to its Board of Directors. Dr. Krishnan has more than 20 years of experience in healthcare, biotechnology and health services.
"Mahesh is a dynamic and highly accomplished healthcare executive, and we are pleased to welcome him to the Halozyme board," said Dr. Helen Torley, president and chief executive officer. "His experience with building and growing business opportunities in addition to his medical expertise, will provide valuable perspective as we expand our leadership as the premier provider of innovative drug delivery technologies."
Dr. Krishnan currently serves as Group Vice President of Growth at DaVita, Inc., one of the largest providers of kidney care services in the U.S. He was co-lead of the DaVita Venture Group, where he oversaw strategic partnerships in technology and research and development within the organization. In his current role, he also oversees aspects of medical policy in Washington, D.C. Dr. Krishnan previously served as DaVita's Group Vice President of Research and Development and was the company's first international Chief Medical Officer. Prior to DaVita, he served in various roles at Amgen Inc., including as the Global Development Leader for Epogen® and Executive Director, Medical Policy for all of Amgen's domestic products. Prior to his time at Amgen, Dr. Krishnan was a practicing nephrologist at Virginia Nephrology Group.
"I am honored to join Halozyme as a board member at such an exciting time for their business," said Dr. Krishnan. "As they continue to innovate with their disruptive drug delivery technologies and execute their patient centric vision, I look forward to leveraging my background and sharing my expertise to support their growth."
Dr. Krishnan earned his B.S. in pre-medicine from The Pennsylvania State University and M.D. from Jefferson Medical College at Thomas Jefferson University. He also holds an M.P.H. from Johns Hopkins University and an M.B.A. in healthcare management from the Johns Hopkins Carey School of Business.
About Halozyme
Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of reducing treatment burden for patients. Having touched more than 800,000 patient lives in post-marketing use in seven commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals.
Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence. The Company has two commercial proprietary products, Hylenex® and XYOSTED®, partnered commercial products and ongoing product development programs with several pharmaceutical companies including Teva Pharmaceuticals and Idorsia Pharmaceuticals.
Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations facility.
For more information visit www.halozyme.com and connect with us on LinkedIn and Twitter.
Roche ad hoc announcement - Phesgo and
Ocrevus comments.
https://www.roche.com/investors/updates/inv-update-2024-04-24
George S. Kaufman
Nein!
OT: In answering your question, I just realized that iHub removed my longstanding avatar photo. He's back now and hopefully will remain undisturbed.
Bonus points if you can ID him.
PS, agreed about Denmark ultimately supporting Wegovy. There's really no reason not to. (Well, except that it might perhaps rub up against their national self-image as that of a nation of fit and trim people.)
OT:
I doubt that obesity is much of a problem in Denmark. When I visited the country, it was easy to spot the Americans in Copenhagen for obvious reasons. But, yes, you'd think they would show some support for their largest company, if only for international PR reasons.
I share your frustration with this management team. The BOD is asleep at the wheel or somehow beholden to Helen and unwilling to act. Evidently, she is very adept at shoring up her flanks preserving her internal power, yet a dismal failure at making profitable commercial deals. I'm at a loss as to how a multi-billion dollar company can drift into paralysis like this, but it seems that there is no answer on the visible horizon. We shareholders are getting more wise to the fact that the Empress has no clothes, and I'd expect that it is also becoming more widely understood as each week goes by. What the consequence of that will be is very uncertain from where I sit, but the PPS is bound to drift lower with each passing week until something changes.
Query: Do you think it possible that Halozyme is simply selling the rhuph20 as a commodity without a partnership deal in order to encourage these trials with the hope that the companies will ultimately be induced to commit to a more traditional deal after seeing positive results?
In any event, thanks for sharing. We can keep our ears peeled the next CC for further references to these potential partnerships.
I couldn't tell from the article whether OSA symptoms were reduced concomitant with weight loss -which would be expected - or were a direct result of the exposure to the drug?
In my opinion, if HALO has contracts with these companies, this is material information that must be disclosed to the general investing public.
HC Wainwright analyst M. Kapoor reiterates BUY and $50 PT.
Benchmark analyst R. Wasserman reiterates BUY with $50 PT.
I would add that the cup and handle formation is also a bullish indicator, FWIW. All I see, though is a stock locked in a very clear, definable pattern, and on the high end of that pattern at that; so, absent news, this is likely going to sag to the mid to low 30s IMHO.
There is adequate cash flow to service the current debt, in my opinion, but that is assuming the management does not make any bonehead moves to tie it up in other pursuits.
Defiinitely is subcu but I don't see any method of action listed in the documentation.
No such deal has been made public to my knowledge. What makes you think they are using hyaluronidase?
Funny. Here's hoping that your're right.
I agree that the patents are material to future income, but I believe that this is baked into the current price and we are not going to break out of the range unless there is hope for future growth. This concern over the lack of new deals is taking the place of the patent cliff worries of recent years and will get more prominently featured in analyst papers going forward.
There is no indication when patents will be granted, but I don't think it will move the needle outside of the current rangebound limits at all. By the way, we've reached the end of the quarter with yet another goose egg for new deals. I'm starting to think that we are being actively lied to when HALO trumpets all the interest in partnerships that are supposedly percolating.
Howee do you believe LaBarre has cancelled his 10b-5 selling plan?
What a slender thread on which to hang one's hopes.
ARGX up as Roche/Chugai autoimmune disease drug disappoints in closely watched trial
BioPharma Dive· Industry Dive
Jonathan Gardner
Thu, Mar 21, 2024, 8:08 AM EDT2 min read
In This Article:
ROG.SW
-2.55%
AZN.L
+2.60%
An autoimmune disease drug from Roche and Chugai Pharmaceutical hit its main goal in a closely watched trial, but the results of the study, in a condition called myasthenia gravis, “did not reach our expectations,” the companies said Thursday.
Roche and Chugai have already brought the drug, known as Enspryng, to market for the rare eye condition neuromyelitis optica spectrum disorder. But the companies are working to expand its use elsewhere, including in myasthenia gravis, an autoimmune condition characterized by muscle weakness.
In recent years, myasthenia gravis has become a competitive area among drugmakers. AstraZeneca’s Soliris and Ultomiris are among the medicines available. More recently, Argenx’s Vyvgart became the first of a newer group of so-called FcRn inhibitors to get to market and has gotten off to a strong launch. Johnson & Johnson and Immunovant are advancing FcRn blockers as well.
Those drugs, though, faced a potential competitive threat from Enspryng. Recently published study results showed that tocilizumab, a drug that works similarly to Enspryng, might be an effective treatment for myasthenia gravis. That, in turn, had stoked fear among investors that the Enspyring trial could establish medicines like it, IL-6 inhibitors, as a “new standard-of-care” with “differentiated efficacy” and less frequent dosing than FcRn drugs, wrote Leerink Partners analyst Thomas Smith, in a note to clients Thursday.
The study tested Enspyrng in a trial that randomized 185 patients to receive the drug or a placebo over 24 weeks. The main goal was to outperform a placebo on a 24-point questionnaire.
Chugai revealed Thursday that Enspyring fell short of expectations on the “degree of clinical benefit” in the trial. The company didn’t provide further details, saving them instead for a medical meeting next month. It’ll continue developing Enspryng for other rare inflammatory conditions, such as thyroid eye disease and autoimmune encephalitis.
In the meantime, the effects of the findings rippled across to other developers. Argenx shared climbed 12% in Thursday morning trading, while Immunovant’s stock initially surged double digits before settling in to a smaller gain. Shares of Tourmaline Bio, which is developing an IL-6 drug for myasthenia gravis, fell nearly 40%.
Smith, of Leerink, expects the results “to be viewed as confirmation of FcRn’s current role as the preferred [target]” for the disease.
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter.
https://finance.yahoo.com/news/roche-autoimmune-disease-drug-disappoints-120800457.html?.tsrc=fin-srch
Hmmm..how do you define "daylight"?
Thanks for the clarification!!
Sorry to sound obstreperous, but there is nothing in that article that indicates Enhanz will be involved in the development of CAB-ULA in either iteration, whether subcu or IM.
Thanks for the Idorsia info. That was a deep dive!
FRom the article you posted recently
While AI's are mentioned in the articles, I didn't see any confirmation that they were ATRS products. Did I miss something?
Interestingly, at Barclays, I noticed Helen mentioned they are seeking potential partnerships in the "nucleic acid"" and "RNA" arena. Is this the first time she has mentioned these potential partners?
In Barclay's fireside chat Helen mentioned there are 7 wave 4 products in development and the slide set says the same, however we now know that the Cabotegravir (ViiV) is off the table so there are in fact only 6.
New competition looming for HALO's epipen AI franchise.
https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-announces-pivotal-study-anaphylmtm
I think you may be correct. My memory of seeing TED indication might have been from the Horizon deal, which seems to have been abandoned in light of Horizon's newer deal with Xeris.
I think you may be correct. My memory of seeing TED indication might have been from the Horizon deal, which seems to have been abandoned.
Howee, also the study is using a pre-filled syringe, not an auto-injector.
I don't think this is a new deal but one that was originally a part of the original ARGX deal which contained multiple targets including thyroid eye disease. I'm not certain about this, though. I do remember seeing something on the (HALO web site maybe?) about that target long before biotechinvestor posted yesterday. Unfortunately HALO chose to take down that useful chart on the partner pipeline so I can't be sure. Bottom line for me is that I'm not treating it as a new target but rather a pre-existing one that is just getting off the ground.
Good pickup, thanks for sharing. Efgartigimod should keep HALO afloat for a while unless ARGX fails another trial.
IM administration of Enhanz is highly speculative and probably not sufficiently efficacious due to the much smaller volume of hyaluronan in muscle tisse as compared to the skin matrix.